-
Views
-
Cite
Cite
Noah Kojima, Annabelle de St Maurice, Earl J Erezo, Erika Yanez, Elizabeth Traub, Allison Joyce, Amy Marutani, Nicole Green, Sharon Balter, Sheree R Poitier, Jan King, Use of Baloxavir Marboxil Post-Exposure Prophylaxis to Halt an Influenza A(H3) Outbreak in a College Sports Team, November 2024, Clinical Infectious Diseases, 2025;, ciaf148, https://doi.org/10.1093/cid/ciaf148
- Share Icon Share
Abstract
Baloxavir marboxil is approved for influenza treatment and post-exposure prophylaxis (PEP). There are limited real-world examples of its use in influenza outbreaks. Here, we describe the use of baloxavir marboxil as PEP to halt an influenza outbreak among a college sports team during the 2024–2025 influenza season.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
You do not currently have access to this article.